Areas of practice
Ms. TAI has more than 27 years’ experience as an IP practitioner, and worked with one of China's largest IP firms for long time as the executive member before joining KWM.
Ms. TAI is one of the most influential figures in IP law in the pharmaceutical and healthcare sectors, and has represented many influential cases including the Viagra® (Sildenafil) and Lipitor® (Atrovastatin) for Pfizer, Brillinta® (Ticagrelor) for AstraZeneca, Xarelto® (Rivaroxaban) for Bayer, Actemra® (Tocilizumab) and Xofluza® (baloxavir marboxil) for Roche/Chugai, Victoza® (Liraglutide) for Novo Nordisk, Entresto® (Valsartan Sacubitril) and Revolade® (Eltrombopag) for Novartis, in the patent invalidation and infringement litigations.
Ms. Tai is recognized in the international intellectual property community as one of the World’s Leading Patent Practitioners and Leading Lawyer by MIP and IAM for many consecutive years. Ms. Tai was named “Eminent Practitioner” in the category of intellectual property non-litigation by Chambers Asia Pacific Guide consecutively from 2016-2020. She was also selected as one of the first National IP Leading Experts and awarded by the then SIPO as one of the “First Leading Patent Attorneys in China”. She is the perennial counselor-at-law of INTERPAT and RDPAC (R&D pharmaceutical association committee).
Her work highlights included but not limited to:
1. Represented Pfizer Inc. in the high-profile Viagra® (Sildenafil) case in both invalidation and court proceedings. After nine years of battle, Ms. Tai eventually secured favorable rulings for the client from Beijing No. 1 Intermediate People’s Court and Beijing Higher People's Court, respectively. The case attracted extensive coverage by domestic and overseas media including The Wall Street Journal and was listed as one of the eight "IP Cases of the Year" in 2008.
2. Represented Pfizer Inc. in an appeal over patent invalidation disputes concerning its blockbuster Lipitor® (Atrovastatin) following unfavorable decisions from Beijing No. 1 Intermediate People’s Court. Ms. Tai ultimately collaborated with other litigators to secure a critical victory before Beijing Higher People's Court .
3. Represented AstraZeneca before Beijing Higher People's Court on the patent invalidation case concerning Brillinta® (Ticagrelor). The case was ruled in favor of the client and selected as one of the top 50 IP cases of year 2018 by the supreme people’s court and deals of the year 2019 by Chinese business law.
4. Represented Novartis on the series of patent invalidation case concerning Entresto® (Sacubitril Valsartan Sodium) and supported by China National Intellectual Property Administration. The case was selected as Deals of the year 2021 by China Business Law Jouranl.
5. Represented Astellas before Beijing Intellectual Property Court on the administrative case concerning Xtandi® (Enzalutamide). The case was ruled in favor of the client.
6. Represented Bayer on the patent invalidation case concerning Xarelto® (Rivaroxaban). The case was selected as Annual Top Ten Cases (2020) of Patent Reexamination and Invalidation Department.
7. Represented Roche on the series of cases concerning Xofluza®. One of these cases was selected as Annual Top Ten Cases (2021) of Patent Reexamination and Invalidation Department.
8. Represented AstraZeneca on the series of cases concerning Forxiga ® (Dapagliflozin). The series of administrative rulings on patent infringement culminated in a successful decision.
In addition, Ms. Tai is also a highly recognized lecturer and project leader in a number of research projects, including:
1. Ms. Tai has been a highly recognized lecturer for many years for the “Patent Reexamination and Invalidation”, an induction training course offered by the All-China Patent Attorneys Association for new patent agents.
2. Ms. Tai participated in the research of the third amendment to the Patent Law. She co-authored a 50,000-word thesis on the nature of the proceedings for invalidation requests which was included in the Research Report on the Third Amendment to the Patent Law and Implementation Rules published by the China National Intellectual Property Administration (CNIPA).
3. She led a team to undertake the soft research project of the CNIPA entitled “Study on the Costs and Strategies for Chinese Applicants Seeking Patent Protections Overseas”
4. She led a team to undertake the research project of China Intellectual Property Society entitled “Comparative Study on Accurate Calculation of Damages for Patent Infringement”.
5. She is team leader for the “Report on the comparative study of Patent Linkage worldwide and implementing proposals in China” (2019), and
6. She is the team leader for the “Report on the stability of compound patent in China” (2020).
7. She is the first author for the book “ Comparative study on patent linkage system”.
8. She is the first author for “Comparative Study on the stability of compound patent”
Ms. Tai started her career in 1993. She joined King & Wood Mallesons in 2019. Prior to this, she worked for China Patent Agent (HK) Ltd as deputy general manager, responsible for the firm’s patent team management and handling of important and complicated cases.
Mr. Tai graduated from Peking University with a bachelor's degree in applied chemistry and a master's degree in polymer radiation chemistry. In 2003, she obtained L.L.M from the University of London.
Her working languages are Chinese and English.